UNSPSC 51171946: Lafutidine

This classification denotes a histamine-2 receptor antagonist with the molecular formula C22H29N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 49S4O7ADLC, chemically known as acetamide, 2-((2-furanylmethyl)sulfinyl)-n-(4-((4-(1-piperidinylmethyl)-2-pyridinyl)oxy)-2-butenyl)-, (z)- but generally known as lafutidine, which bears US NIH Compound Identifier 5282136. European Medicines Agency schedules Lafutidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08388MIG.

UNSPSC 51171946 Lafutidine is a Commodity code representing pharmaceutical products procured by state and local government entities for clinical and correctional health programs. State and local buyers under this code are acquiring pharmaceutical inventory and related specimen testing services for offender supervision, employee health plans, and multistate cooperative purchasing networks. The issuing bodies include county community supervision departments, state health and human services commissions, and multistate cooperative purchasing alliances administering agreements on behalf of participating state agencies and local governments. The work spans direct pharmaceutical supply contracting, pharmacy benefit program design and fulfillment, and specimen collection and drug testing services using pharmaceutical screening methodologies.

Recent activity shows Collin County (Texas) Community Supervision and Corrections Department issuing RFP 2026-327 for offender specimen collection and drug testing services with proposals due July 23, 2026, estimated contract value of $600,000, and a two-year term commencing September 1, 2026 with three optional one-year renewals; the Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription programs for the state's pharmacy benefit initiative; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026 and an effective date of July 1, 2026 for awarded vendors to supply participating state and local facilities across Minnesota and Oregon. Activity is concentrated in Texas and Minnesota, with the code showing active procurement across correctional health, state employee benefits, and multistate cooperative purchasing vehicles serving multiple jurisdictions.